Trial Profile
Venetoclax in Chronic Lymphocytic Leukemia Effectiveness and Real-life Treatment Management
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms VERONE
- Sponsors AbbVie
- 15 Jun 2023 Interim results assessing treatment effectiveness and tolerability in routine medical practice, presented at the 28th Congress of the European Haematology Association.
- 25 Jan 2023 Planned primary completion date changed from 31 Dec 2022 to 30 Jun 2026.
- 07 Jul 2022 Status changed from recruiting to active, no longer recruiting.